What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012

Similar documents
This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

The oncology specific domains TU, TR and RS: What to know as a statistical analyst

Carcinosarcoma Trial rial in s a in rare malign rare mali ancy

Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

The pcodr review also provided contextual information on ALK mutation testing.

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

PRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse

Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles

National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups

Happy New Year in 2017!!! Year of Rooster

pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO

The STAR Trial: Can Quality of Life Benefit Offset Any Survival Detriment? Summary

Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Integrating Imaging Criteria Into Trial Endpoints

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

DISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board

CONTEXT OF THE RESUBMISSION EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT


Initial Recommendation for Olaparib (Lynparza) for Ovarian Cancer perc Meeting: July 21, pcodr PAN-CANADIAN ONCOLOGY DRUG REVIEW 4

The DATECAN initiative

ClinicalTrials.gov a programmer s perspective

OVERALL CLINICAL BENEFIT

Radiographic Assessment of Response An Overview of RECIST v1.1

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.

WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example

Synopsis. Study Phase and Title: Study Objectives: Overall Study Design

RECIST 1.1 and SWOG Protocol Section 10

Understanding Clinical Trials

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Clinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.

Regulatory Challenges in Reviewing Oncology Product Applications

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better?

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective

Eribulin for locally advanced or metastatic breast cancer third line; monotherapy

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

Dr Roopinder Gillmore July 2017

Tumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016

Electronic Capture of PROs in NCI Clinical Trials

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

ASH POSTER: LYMRIT UPDATE

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

National Cancer Institute Clinical Trial Cooperative Groups

Cancer Biomarkers: Hope, Hype or Help. Does the past predict the future?

risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.

acceptance of PFS as a clinically meaningful endpoint and its agreement with the CGP that PFS is a likely surrogate of OS in MTC.

Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

XII Michelangelo Foundation Seminar

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer

1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016

Life Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop

FDA grants Roche s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018

NSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania

ASSESSING LONG-TERM BENEFITS OF IMMUNOTHERAPY BASED ON EARLY TUMOR ASSESSMENT DATA

ArQule Jefferies Global Healthcare Conference June 2015

PTAC meeting held on 5 & 6 May (minutes for web publishing)

Cabozantinib for medullary thyroid cancer. February 2012

Clinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat

Possibilities and risks associated with directly moving from Phase I to Phase III: Adaptive designs and Co

QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies


PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

CPAG Summary Report for Clinical Panel 1608 Bendamustine for relapsed multiple myeloma

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

Patient-Centered Endpoints in Oncology

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb


MEET MARY KISQALI PATIENT PROFILES

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Idera Pharmaceuticals

OVERALL CLINICAL BENEFIT

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes

Analysis of Oncology Studies for Programmers and Statisticians

Clinical Study Synopsis

INMUNOTERAPIA I. Dra. Virginia Calvo

ARQ 087 Overview. FGFR Inhibitor. March 2017

Basket and Umbrella Trial Designs in Oncology


9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO

Media Release. Basel, 18 February 2017

Statistical validation of biomarkers and surogate endpoints

Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial

pan-canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Gastrointestinal Stromal Tumors

PCI Biotech press release 24 th August Attachment

Transcription:

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012

Disclaimer The opinions expressed in this presentation and on the following slides are solely those of the presenter and not necessarily those of Novartis. Novartis does not guarantee the accuracy or reliability of the information provided herein 2 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Introduction Whether you are a SAS programmer in pharmaceutical industry, a bank or insurance company your job is to: restructure data sets program statistical analyses create reports according to the provided requirements and specifications. With a few differences Even if still SAS is SAS and statistical reporting is still about tables, figures and listings. Wrong: Oncology is special! 3 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Agenda Special Disease Special Data Special Analyses Special Reporting Conclusion

Special Disease Oncology is a very rapidly developing area in medicine, but also in science. The investigation of molecular pathways and genetic mutations involved in tumour genesis is ongoing. Oncology will be the biggest therapeutic area in 20 years! A sense of Urgency Many cancers develop very fast, and most clinical trials start as second line treatments of advanced carcinomas - Patients median survival time as short as 6 months. - In Oncology clinical trials are either accelerated, priority or on fast track. 5 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Disease Trial design Ethics Placebo control arm or not - Settings: prevention, adjuvant, or early disease - Placebo-alone control usually not feasible in advanced cancer Pot practical and ethical for cancer patient use a placebo-alone treatment arm Placebo possible in combination therapy 6 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Data Special Schedule: CRF organised in Cycle and not in Visit Tumor Assessment Concomitant medications: Drug/drug interaction Additional data -> identify subpopulation for targeted therapies Biomarkers Challenge for Programming: - Always difficult to plan Programming for Biomarkers: Late timelines Standard Data structure is difficult -> often done in small local laboratories 7 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Data CTCAE grades In Oncology, Laboratory grades are derived following the NCI-CTCAE definition: - The NCI-CTCAE 4.2 (National Cancer Institute - Common Terminology Criteria for Adverse Events) provides definitions for AE terms and a grading (severity) scale for each AE. Eg below: Challenge for Programming: - Use of local and/or Central lab - Conversion in standard Units - Missing units is also a problem when converting - Missing Lower/Upper Normal Ranges 8 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Data Dosing information Compliance: Relative Dose Intensity (RDI) - RDI is a term that refers to the amount of a particular treatment given over a specific time in relation to what was ordered Dose reduction: A reduction is defined as a decrease in dose from the protocol planned dose or a decrease from the previous non-zero dose Dose interruption: An interruption is defined as a 0mg/0tablets dose given on one or more days. Challenge for Programming: - Dealing with dosing in relation to cycles - Definitions and derivations with differents time schedule, unit... 9 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Analyses Clinical Trial Endpoints Disease Free Survival (DFS) -> Recurrence, Death Progression Free Survival (PFS) -> Progression, Death Overall Survival (OS) -> Death Quality of Life (QoL) -> Side effect of the treatment, symptoms of the disease - EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30) - FACT x (Functional Assessment of Chronic Illness Therapy) -... 10 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Analyses Clinical Trial Endpoints (next) Overall Response Rate -> sum of partial response (PR) plus complete response (CR) - For solid tumor the gold standard is provided by RECIST (Response Evaluation Criteria In Solid Tumors) criteria published in 2000 by the European Organisation for Research and Treatment of Cancer (EORTC), NCI, and the National Cancer Institute of Canada Clinical Trials Group. - For Malignant Lymphoma CHESON (Revised Response Criteria for Malignant Lymphoma) -... Challenge for Programming: RECIST is a complex algorithm with a lot of specifications to take into account... 11 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Analyses How to derive the Time point response? - Based on Tumor Assessment results - Target Lesions response - Non-Target Lesions response - Presence of New Lesions Ref: Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247 Challenge for programming: - RECIST is simple. Using RECIST is not 12 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Analyses Interim Analyses Analysis intended to assess treatment effect with respect to efficacy or safety at any time prior to completion of the clinical trial Ethical, Economic / Efficient, Scientific, Administrative Independent Data Monitoring Committee (IDMC) Group of experts external to the study that reviews on regular basis accumulating data from an ongoing clinical trial An on-going review and evaluation of safety data and possibly efficacy data for one study or several studies within a development program. Challenge for programming: Studies can be stopped prematurely Incomplete nature of the data and not fully cleaned Event driven analyses - Deliverables/timelines accelerated 13 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Reporting Planning of Programming Activities is challenging: First need finalized Statistical Analysis Plan and Tables shells Programmer must be flexible as: - Target is moving: Data Base Lock depending on Last Patient Last Visit (LPLV) Timelines and Resources estimation to be reviewed regularly - Importance of standard CRF, Data, output shells and programs to improve efficiency 14 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Special Reporting Pooled analyses for post-approval commitments Oncologic Drugs Advisory Committee (ODAC) in USA Yearly updates of the clinical study report until study end Challenge for programming: To be ready on time even if the target is moving To standardize programming 15 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Conclusion Oncology is very challenging and very exciting for a Statistical Programmer: ONCOLOGY IS SPECIAL To be one of the pioneers To deal with the moving timelines To understand and program algorithms such as the Lab Grading and RECIST To set-up the macros, programs and all dependencies to be ready for anything To unify derivations and naming conventions across studies for easier pooling To improve the lives of patients and caregivers 16 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only

Contact Informations Novartis Oncology - Johanna Mursic Indication Programmer johanna.mursic@novartis.com Special Thanks to Kamila Duniec!! 17 What makes Oncology special? Johanna MURSIC 15OCT2012 PhUSE congress Budapest Business Use Only